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Summary
Introduction
　Dental treatment using propofol (trade name Diprivan) was carried out for people with 
disabilities who have difficulties with dental treatment so that dental treatment could be 
carried out safely and smoothly. This time, we investigated for the purpose of clarifying 
the factors of those who need 3.5 µg/ml or more when sedated with propofol.
Object and method
Methods
　The subjects were 34 persons, who required the intravenous anesthesia method at the 
time of dental treatment, among patients who visited Matsumoto Dental University Hos-
pital special specialist department from May 1st to September 30th, 2015. Gender, age, pres-
ence or absence of regular medications were noted, weight and height were measured, and 
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medical record were entered on the survey form. As an evaluation of adaptability to dental 
treatment, they were classified into 4 stages: “Can sit on the medical table”; “Can sleep the 
treatment table”; “Can do an oral examination”; and “Can do PTC”.
　The diffuser TCI function was used to initiate intravenous administration at the target 
blood concentration of 3.0 µg/ml. Dental treatment was started with blood concentration in 
the brain when the opening device was smoothly inserted. If this target was not possible, 
0.2 µg/ml each was listed. Blood concentrations and intracerebral concentrations of propo-
fol during treatment were recorded. The intracerebral concentration where the opening de-
vice was smoothly inserted, the lowest brain concentration and the maximum brain con-
centration at the time of treatment were also recorded.
Result
　34 subjects (28 males, 6 females) had an average age of 37.6±12.4 years. The items asso-
ciated with brain concentration of propofol were subjects aged 50 years or older (P = 0.01), 
BMI (P = 0.15), dental phobia (P = 0.001), and autistic spectrum disease (P = 0.07).  The fac-
tor that required propofol brain concentration of over 3.5 µg/ml was dental phobia (odds 
ratio: 28.5: confidence interval 1.₉–421) by the logistic regression analysis.
Conclusion
　A factor that requires propofol of 3.5 µg/ml or more at the time of dental treatment, for 
those who can assume a supine position without making refusing actions at the medical 
table, was dental phobia. There was no relevance to the content of treatment or to the 
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